Purpose: To evaluate the efficacy of a novel multiday schedule of vinorelbine and cisplatin in patients with advanced NSCLC.
Introduction
Weekly vinorelbine improves survival in advanced NSCLC [1, 2] but treatment outcomes remain unsatisfactory, emphasizing the need for developing more active schedules of this drug. Vinorelbine demonstrates time-dependent cytotoxicity in vitro [3] , and has a terminal half-life longer than 24 hours when administered at doses of 15-30 mg/m 2 in vivo [4] . On the basis of these properties, it was postulated that a multiday vinorelbine dosing schedule would maximize efficacy by exposing tumor cells to repetitive vinorelbine peak levels, and by increasing the drug exposure duration to a period of several days. We previously demonstrated the feasibility of daily x 4 vinorelbine and cisplatin, at doses of 15 mg/m 2 /day and 20 mg/m 2 /day respectively [5] . Based on the observed promising antitumor activity, this fourday vinorelbine-cisplatin schedule, was chosen for further phase II evaluation. than grade 2. Patients were informed of the investigational nature of the study and written informed consent was obtained.
Pretreatment evaluation consisted of history and physical examination, complete biochemical profiles, CT scans of head, chest, and abdomen, and bone scan. Responses were assessed after completion of the second cycle and confirmed after the fourth cycle. No further chemotherapy was allowed beyond the four planned cycles until documented disease progression.
This regimen was designed for outpatient administration. Vinorelbine was administered at a daily dose of 15 mg/m 2 by rapid intravenous (i.v.) injection, on days 1 through 4, followed by cisplatin, at a daily dose of 20 mg/m 2 , given i.v. over one hour, on days 1 through 4. Adequate i.v. hydration with 1 1 of fluids, and i.v. antiemetics, consisting of dexamethasone 20 mg and ondansetron 20 mg, were given daily prior to cisplatin. Prophylactic filgrastim 5 ug/kg, was administered subcutaneously, beginning 24 hours after chemotherapy completion and continuing until the post-nadir white count was greater than 10000/ul. Cycles were repeated every 21 days. Vinorelbine doses were permanently reduced by 50% for febrile neutropenia, and cisplatin was reduced by 50% for nadir platelet counts less than 50,000/ul.
The primary end-point was response rate. Because the response rate for standard weekly vinorelbine plus cisplatin in similarly staged patients is approximately 25% [2] , we considered that a response rate greater than 40% would justify further study of this schedule.
Patients and methods
Chemotherapy-naive patients with histologically confirmed NSCLC, stage IV, or stage IIIB with pleural involvement not amenable to treatment with chemoradiation, were eligible. All patients had bidimensionally measurable disease; a Southwest Oncology Group (SWOG) performance status (PS) of 0-2; absolute neutrophil count (ANC) > 1500/ul, platelet count > 100,000/ul, total bilirubin level < 2 mg/dl, serum creatinine <1.5 mg/dl; and peripheral neuropathy no worse
Results
Thirty eligible patients were registered (Table 1) , representing 55% of all potentially eligible patients referred to our group during the study time period, and 81% of those considered for combination chemotherapy. The median number of metastatic sites was 2 (range 1-4), including bone in 16 patients, liver in 6, CNS in 5, and subcutaneous tissue in 4 patients. Only five patients (17%) had exclusively extrathoracic nodal, or lung-tolung metastases. Toxicities observed during 89 cycles of chemotherapy are summarized in Table 2 . There were three early deaths not caused by tumor progression. One death was treatment-related, caused by pneumonia during a period of profound neutropenia, in a patient who was on dexamethasone for brain metastases. The other two deaths were due to pulmonary embolism, and refractory Trousseau's syndrome.
The most prominent hematologic toxicity was neutropenia. Overall, 20 patients (69%) experienced at least one episode of grade 4 neutropenia, with a median time to neutrophil nadir of 9 days (range 7-12 days). The duration of grade 4 neutropenia was brief, with a median time to a neutrophil count >500/ul of three days (range one to six days). Despite prophylactic filgrastim, 48% of patients experienced at least one episode of febrile neutropenia, with two documented infections (urinary tract and pneumonia). Febrile neutropenia complicated 16% of all chemotherapy cycles, including 20% of the 71 cycles given at full vinorelbine doses, whereas there were no episodes of febrile neutropenia during 18 cycles given at 50% vinorelbine doses. The risk for febrile neutropenia was 52% for cycles producing neutrophil nadirs of less than 100/u!, as compared to 14% for cycles with neutrophil nadirs of 100-500/ul (Fisher's exact test P = 0.03). Four patients developed severe anemia with hemoglobin levels of less than 8 g/dl, and three patients had severe thrombocytopenia with nadir platelet counts less than 20,000/ ul. Five patients required transfusion support, receiving a total of 10 units of packed red blood cells, and six units of platelets.
The most prominent nonhematologic toxicity was delayed nausea and vomiting. Grades 3 and 4 emesis, were noted in six and four patients respectively. Eight patients received i.v. hydration, and seven of them were treated as outpatients. The median duration of emesis was three days (range one to four days). Severe constipation was observed in four patients. Transient but noncumulative asthenia was common. Partial-to-complete alopecia was universal. Stomatitis, phlebitis, and asymptomatic liver enzyme elevation occurred infrequently. Neurotoxicity, ototoxicity, and renal toxicity were not observed in this study.
The mean dose intensity of cisplatin was 24.2 mg/m 2 / week (range 12.2-29.4), whereas the mean dose intensity of vinorelbine was 16.8 mg/m 2 /week (range 9.2-20.2). The median duration of treatment was 2.7 months (range 0.7-3.1 months). The average treatment cost per patient was estimated at USS 13,900.
The overall response rate was 53% (16 of 30, 95% CI: 34%-72%), with 2 complete and 14 partial responders. The median duration of response was 5.3 months (range 3.8-10.4 months). The median event-free survival was 4.6 months (range 0.3-21.2+ months). Upon disease progression, 15 patients received docetaxel-based second line chemotherapy with 6 responses.
The median survival duration was 8.1 months, with actuarial 12-month and 24-month survival probabilities of 40% and 15%. Patients with performance status of 0-1 survived longer than patients with performance status of 2 (median survival 12.2 months vs. 4.9 months, log-rank, P -0.02), with 12-month survivals of 58% vs. 9% and 24-month survival rates of 18% vs. 9%.
Discussion
In this group of patients, four cycles of a four-day vinorelbine and cisplatin schedule resulted in a received vinorelbine dose intensity of 16.8 mg/m 2 /week, associated with a response rate of 53%, and a median event-free duration exceeding the median treatment duration. The delivered vinorelbine dose intensity was only 75%-80% of the dose intensities obtainable with standard vinorelbine-cisplatin schedules [1, 2, 6] , but it resulted in a higher response rate, suggesting enhanced antitumor activity with multiday vinorelbine dosing.
As compared to a recently reported phase III study of weekly vinorelbine plus monthly cisplatin in similarly staged patients [2] , the present multiday schedule delivered a lower vinorelbine dose intensity (16.8 vs. 21.2 mg/m 2 /week) and yet produced more frequent grade 4 neutropenia (69% vs. 59%), and febrile neutropenia (48% vs. 10%) raising the question of enhanced daily vinorelbine toxicity on myeloid precursors. Whereas the duration of severe neutropenia was generally brief, nadir neutrophil counts less than 100/ul were common and significantly increased the risk for febrile neutropenia. Documented infections were infrequent and the re-occurrence of febrile neutropenia during subsequent cycles could be prevented by halving the vinorelbine doses.
A high proportion of patients enrolled in the study had metastatic disease (90%), and poor performance status (37%). In view of these known [7] [8] [9] adverse prognostic factors, the 12-and 24-month survival rates of 40% and 15% are encouraging.
In conclusion, this four-day schedule of vinorelbine and cisplatin is highly active against advanced nonsmall-cell lung cancer, but it does not result in an improved therapeutic index over the standard schedule, due to the high frequency of neutropenic complications. This schedule is worth further exploration, through a reduction of its duration to three consecutive days, aiming to reduce the severity of acute neutropenia while maintaining efficacy.
